Aneurysmal subarachnoid hemorrhage represents a severe neurological crisis that requires immediate endovascular or microsurgical intervention. Over recent years, flow diverter embolization has emerged as a promising reconstructive approach for challenging cerebrovascular lesions. Interventionalists traditionally reserved these devices for unruptured lesions. However, acute applications in ruptured aneurysms are increasing rapidly. Endovascular reconstruction alters hemodynamics within the parent vessel, thereby promoting progressive thrombosis of the aneurysm sac. Nevertheless, acute deployment requires potent antiplatelet therapy, creating complex perioperative management dilemmas. Recently, a nationwide inpatient study evaluated clinical outcomes among 62,567 patients admitted with nontraumatic subarachnoid hemorrhage. The study compared the pipeline embolization device directly against conventional coil embolization. Consequently, these findings illuminate critical differences in systemic bleeding risks, clinical selection patterns, and postprocedural morbidity.

Expanding Indications for Flow Diverter Embolization in Ruptured Aneurysms

Historically, neurointerventionalists reserved flow diverters for wide-necked, large, or giant unruptured intracranial aneurysms. Today, clinicians increasingly deploy flow diverter embolization for complex ruptured vascular morphologies. These difficult lesions include dissecting, blister-like, and nonsaccular aneurysms that defy conventional surgical clipping or endosaccular coiling. Standard coil embolization in such unstable vessel walls carries high risks of intraprocedural rupture and recurrent canalization. In contrast, flow-diverting stents establish a dense mesh across the diseased parent artery. This mesh redirects blood flow away from the fragile aneurysm dome while preserving vital branch vessels. Over subsequent months, endothelial tissue grows across the neck, reconstructing the arterial lumen permanently. However, using these devices in acute subarachnoid hemorrhage carries significant biological hurdles. The primary obstacle involves mandatory antiplatelet medication to prevent stent thrombosis. Therefore, clinicians must carefully weigh the architectural advantages of endoluminal reconstruction against dangerous acute hemorrhagic hazards.

Systemic Hemorrhagic Complications and Extracranial Risks

The nationwide inpatient study revealed striking differences in non-neurological complications between treatment modalities. Specifically, patients who received flow diverters experienced substantially higher rates of systemic hemorrhagic events than those who underwent coiling. Gastrointestinal bleeding occurred in 5.1% of flow diverter patients compared to only 2.2% in the coiling group. Additionally, respiratory tract bleeding was significantly elevated, affecting 3.2% of flow diversion cases versus 1.3% of coiling cases. These extracranial hemorrhages occur primarily because flow diverters mandate aggressive dual antiplatelet therapy. In contrast, primary coil embolization typically avoids systemic antiplatelet regimens during the acute phase. Furthermore, the analysis showed elevated rates of acute kidney injury and systemic sepsis among flow diverter recipients. These systemic insults exacerbate secondary brain injury and prolong intensive care hospitalization. Therefore, neurocritical teams must monitor organ function vigilantly. Early identification of occult mucosal hemorrhage remains essential to prevent sudden hemodynamic instability.

Patient Selection Patterns in Real-World Subarachnoid Hemorrhage

The registry data clearly illustrated conservative clinical adoption of flow diversion for ruptured aneurysms. Out of 62,567 subarachnoid hemorrhage admissions, only 409 patients, or 0.65%, received pipeline embolization devices. Meanwhile, 6,834 patients, representing 10.9%, underwent standard coil embolization. The remaining majority received either surgical clipping or medical neurocritical management. Interventionalists primarily selected flow diverters when aneurysm neck configuration made stable coil retention impossible. Furthermore, multivariable statistical models confirmed that patient age, clinical comorbidities, and baseline severity heavily influence device choice. Younger patients with dissecting or nonsaccular lesions were significantly more likely to receive flow diversion. Conversely, older individuals with substantial vascular calcification or elevated bleeding risks more frequently received coiling. Moreover, admission neurological grade dictated intervention strategy. Patients presenting with poor neurological status often required invasive intracranial monitoring, which directly constrained the safety of antiplatelet administration. Consequently, clinical teams tailored selection carefully to balance anatomic complexity against procedural safety.

Managing Antiplatelet Regimens and External Ventricular Drains

One of the greatest clinical challenges in acute flow diversion involves reconciling antiplatelet therapy with neurosurgical procedures. Acute aneurysmal rupture frequently induces acute hydrocephalus, requiring urgent external ventricular drain placement. However, inserting an intracranial catheter during active dual antiplatelet therapy significantly elevates the risk of fatal tract hemorrhage. Therefore, neurosurgical consensus recommends inserting ventricular drains prior to administering antiplatelet loading doses whenever feasible. In addition, neurointerventionalists increasingly employ modern surface-modified flow diverters designed to decrease thrombogenicity. These innovative coated devices may soon reduce the intensity and duration of required antiplatelet regimens. Meanwhile, clinical teams utilize point-of-care platelet reactivity assays to guide therapy precisely. These tests identify clopidogrel resistance and prevent excessive platelet inhibition. Thus, close multidisciplinary collaboration between neurosurgeons, interventionalists, and intensivists is vital. Coordinated protocols minimize hemorrhagic events while successfully protecting intracranial stents from catastrophic thrombosis.

Clinical Perspectives and Protocols for Practice in India

In Indian tertiary neurovascular centers, endovascular treatment for ruptured aneurysms has expanded rapidly. However, clinical patterns reflect distinct socio-economic realities and infrastructural constraints. Coil embolization remains the primary endovascular modality across Indian public and private hospitals due to familiarity and affordability. In contrast, flow diversion represents a high-cost intervention requiring specialized operator expertise and advanced intensive care monitoring. Furthermore, managing dual antiplatelet therapy in acute subarachnoid hemorrhage presents heightened operational risks in resource-limited settings. Routine platelet function testing and rapid reversal agents are not universally available across peripheral centers. Therefore, Indian clinicians must exercise strict patient selection criteria when contemplating acute flow diversion. Teams should initiate routine gastrointestinal prophylaxis using proton pump inhibitors for all stented patients. Additionally, centers must establish clear referral pathways to tertiary neuro-ICUs equipped for advanced neuro-monitoring. By reserving flow diversion for untreatable blister or dissecting lesions, Indian practitioners can maximize therapeutic success while avoiding devastating systemic bleeding.

Future Directions: Surface Modifications and Tailored Neuroprotection

The future of neuroendovascular treatment relies heavily on advancing device biocompatibility and individualized pharmacological strategies. Next-generation flow diverters feature innovative antithrombotic surface coatings, such as phosphorylcholine or hydrophilic polymer layers. These biomimetic surfaces reduce platelet adhesion, potentially allowing safe deployment under single antiplatelet therapy. Consequently, future interventionalists may achieve robust flow diversion without exposing acute subarachnoid hemorrhage patients to excessive hemorrhagic risks. Moreover, ongoing clinical trials are evaluating short-acting intravenous antiplatelet agents like cangrelor. Cangrelor offers rapid onset and swift clearance, providing precise pharmacological control during acute external drain placement or urgent surgical procedures. In addition, artificial intelligence and advanced computational fluid dynamics now enable personalized procedural planning. These computational tools simulate intra-aneurysmal hemodynamic shifts before stent deployment, maximizing occlusion efficacy. Ultimately, combining improved surface technology with tailored antiplatelet protocols will significantly broaden the safety window for reconstructive endovascular interventions in acute cerebrovascular emergencies.

Why does flow diverter embolization cause more systemic bleeding than coiling?

Flow diverter embolization requires prompt dual antiplatelet therapy to prevent acute device thrombosis along the endoluminal construct. Conversely, conventional coil embolization typically does not mandate immediate intensive antiplatelet regimens. Consequently, sustained platelet inhibition significantly increases the vulnerability of mucosal surfaces, predisposing patients to gastrointestinal and respiratory tract bleeding.

When should interventionalists choose flow diverters over coiling in ruptured aneurysms?

Clinicians generally reserve flow diverters for complex vascular anatomies where standard coiling or microsurgical clipping is technically infeasible. Specifically, blister-like aneurysms, dissecting lesions, and wide-necked sidewall aneurysms benefit most from endoluminal flow redirection. However, operators must balance these structural advantages against the patient's acute hemorrhagic status and external ventricular drainage requirements.

How can clinical teams mitigate hemorrhagic complications during flow diversion?

Multidisciplinary teams should place external ventricular drains before initiating antiplatelet therapy whenever clinically possible. In addition, clinicians must administer prophylactic proton pump inhibitors to prevent stress ulceration. Finally, utilizing point-of-care platelet function assays and adopting surface-modified flow diverters helps achieve effective thromboprotection while minimizing unnecessary systemic bleeding risks.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult qualified healthcare providers with any medical questions. Refer to the latest local and national guidelines for clinical practice.

References

1. Pando A et al. Flow Diverter Assisted Embolization of Ruptured Aneurysms is Associated with Increased Hemorrhagic Complications: Prognostic Factors and Outcomes in Neuroendovascular Treatment of Subarachnoid Hemorrhages. World Neurosurg. 2025 Jul. doi: 10.1016/j.wneu.2025.124061. PMID: 40349917.
2. Gajjar AA, Srinivasan VM. Letter to the Editor Regarding "Flow Diverter Assisted Embolization of Ruptured Aneurysms is Associated with Increased Hemorrhagic Complications: Prognostic Factors and Outcomes in Neuroendovascular Treatment of Subarachnoid Hemorrhages". World Neurosurg. 2025 Sep;201:124173. doi: 10.1016/j.wneu.2025.124173.
3. Cagnazzo F et al. Flow-diverter devices for the treatment of ruptured intracranial aneurysms: a systematic review and meta-analysis. J NeuroIntervent Surg. 2020;12(4):396-402. doi: 10.1136/neurintsurg-2019-015344.